James Gruber
Director of Finance/CFO en ETON PHARMACEUTICALS, INC. .
Fortuna: 13 496 $ al 31/03/2024
Perfil
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. He previously worked as the Vice President & Controller at Horizon Therapeutics, Inc. Gruber received an undergraduate degree from Indiana University and an MBA from Kellogg School of Management.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 13/02/2024 | 3 599 ( 0.01% ) | 13 496 $ | 31/03/2024 |
Cargos activos de James Gruber
| Empresas | Cargo | Inicio |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Director of Finance/CFO | 11/04/2022 |
Antiguos cargos conocidos de James Gruber.
| Empresas | Cargo | Fin |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Formación de James Gruber.
| Indiana University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
- Bolsa de valores
- Insiders
- James Gruber
